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doi:10.1016/j.jtcvs.2005.11.006ackground: Cardiac surgical procedures can be associated with significant mor-
idity and mortality. Recently, it has been recognized that statins might induce
ultiple biologic effects independent of lipid lowering that could potentially ame-
iorate adverse surgical outcomes. Accordingly, this study tested the central hypoth-
sis that pretreatment with statins before cardiac surgery would reduce adverse
ostoperative surgical outcomes.
ethods: Demographic and outcomes data were collected retrospectively for 3829
atients admitted for planned cardiac surgery between February 1994 and December
002. Statin pretreatment occurred in 1044 patients who were comparable with
on–statin-pretreated (n  2785) patients with regard to sex, race, and age. Primary
utcomes examined included postoperative mortality (30-day) and a composite
orbidity variable.
esults: The odds of experiencing 30-day mortality and morbidity were significantly
ess in the statin-pretreated group, with unadjusted odds ratios of 0.43 (95%
onfidence interval [CI], 0.28-0.66) and 0.72 (95% CI, 0.61-0.86), respectively.
isk-adjusted odds ratios for mortality and morbidity were 0.55 (95% CI, 0.32-0.93)
nd 0.76 (95% CI, 0.62-0.94), respectively, by using a logistic regression model and
.51 (95% CI, 0.27-0.94) and 0.71 (95% CI, 0.55-0.92), respectively, in the
ropensity-matched model, demonstrating significant reductions in 30-day morbid-
ty and mortality. In a subsample of patients undergoing valve-only surgery (n 
16), fewer valve-only patients treated with statins experienced mortality, although
hese results were not statistically significant (1.96% vs 7.5%).
onclusions: These findings indicate that statin pretreatment before cardiac surgery
onfers a protective effect with respect to postoperative outcomes.
ommon cardiovascular surgical procedures include coronary artery bypass
grafting (CABG), as well as valve repair and replacement. Although ad-
vancements in surgical technique and postoperative care have resulted in
ecreasing mortality and morbidity rates for these procedures,1,2 significant com-
lications still occur. Thus identifying pretreatment strategies, such as pharmaco-
ogic interventions, that would favorably affect morbidity and mortality after sur-
ical intervention remains an area of significant clinical interest.
A class of pharmacologic compounds that have stimulated significant interest
ith respect to the prevention of cardiovascular events are the 3-hydroxy-3-
ethylglutaryl coenzyme A reductase inhibitors (statins).3-6 For example, the Heart
rotection Study, a randomized placebo-controlled trial of more than 20,000 pa-
The Journal of Thoracic and Cardiovascular Surgery ● Volume 131, Number 3 679
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CSPients, conclusively demonstrated the ability of statins to
educe major cardiovascular events. Of note, this past study
emonstrated that patients with normal baseline cholesterol
evels also received as much benefit from statin therapy as
hose with increased low-density lipoprotein (LDL) choles-
erol levels. In addition to other in vitro and in vivo studies,
his report suggested that statins modify a number of cellu-
ar and extracellular processes that might be independent of
irect lipid lowering.7,8 For instance, past studies have
uggested that statins might have a beneficial effect on
ndothelial function in the context of hypertensive heart
isease and diabetes.9-11 Other studies have suggested that
tatins might modify the release of biologically active mol-
cules (eg, tumor necrosis factor ) during and after myo-
ardial ischemia.12 In light of these pleiotropic effects, it has
een postulated that statin treatment might have beneficial
ffects in the context of cardiac surgery.13,14 Other studies
ave identified that statin treatment after CABG might
avorably modify long-term morbidity and mortality.15,16
ccordingly, the present study was designed to test the
entral hypothesis that a significant risk reduction with
espect to major early postoperative events would occur in
atients receiving statin treatment preoperatively compared
ith those patients without statin treatment undergoing car-
iac surgery. Although the penetrance of statin treatment in
atients with coronary artery disease has increased over the
ast decade, a relatively high percentage of patients present
or cardiac surgery without a prior history of statin treat-
ent. In view of that, we conducted a retrospective study
sing logistic regression modeling and propensity score
ethodology to determine the effect of statin pretreatment
n 30-day mortality and morbidity after cardiac surgery.
ethods
tudy Design
ince 1993, all patients undergoing cardiac surgery at the Medical
niversity of South Carolina have had their demographic and
perative data entered into a registry. Preoperative use of statins in
his cohort of surgical patients increased from less than 20% before
997 to more than 60% in 2000. The availability of these demo-
raphic, operative, and medication data allowed a retrospective
valuation of outcomes for patients treated with statins before
urgical intervention versus those without while controlling for
ther potential confounding variables. This retrospective study was
pproved by the Institutional Review Board of the Medical Uni-
Abbreviations and Acronyms
CABG coronary artery bypass grafting
CI  confidence interval
LDL  low-density lipoprotein
MI myocardial infarctionersity of South Carolina and conformed to all institutional review f
80 The Journal of Thoracic and Cardiovascular Surgery ● Marcoard and Health Insurance Portability and Accountability Act
equirements.
atient Population
atients included in the cohort were 18 years of age or older and
resented for nonemergency CABG, valve replacement, and/or
alve repair surgery requiring cardiopulmonary bypass during the
tudy period (1994-2002). Any patient presenting for operations
nvolving congenital heart conditions were excluded from this
nalysis. The study cohort consisted of 3829 patients. Statin pre-
reatment occurred in 1044 patients.
tudy Data
he surgery database used in this study was a complete patient
atabase containing demographics, patient history, medical record
nformation, intraoperative data, and postoperative outcome data.
t mirrored the template for the current registry maintained nation-
lly by the Society of Thoracic Surgeons.17 This surgical database
as merged with the hospital pharmacy database in which all
dmission and discharge medications are recorded for each patient.
utcome Measures
ll outcomes were prespecified. Fatal and nonfatal outcomes were
efined as follows: mortality occurring operatively or in the 30-day
eriod postoperatively; myocardial infarction (MI); stroke or ce-
ebral vascular event; hemodynamic collapse; reoperation; or a
omposite morbidity variable that included the occurrence of any
f the morbidity outcomes. Outcomes were adjudicated by all
ttending cardiothoracic surgeons and intensivists at a weekly
urgical morbidity and mortality conference.
ariable Selection
he variables analyzed included demographic variables; preoper-
tive, intraoperative, and postoperative data; and medication data.
ichotomous and categoric variables included variables such as
ace and sex and variables indicating the type of surgical procedure
eg, isolated CABG, CABG with valve repair, and isolated valve
epair), as well as the presence or absence of comorbidities.
ontinuous variables measured were age and body surface area.
ariable selection for the logistic model initially involved pre-
pecification of the model by using clinician input for relevant
ovariates, as well as a literature review of predictive mortality and
orbidity models in cardiac surgery.18-20 Variables selected for
nclusion in the model included patient age, sex, race, preexisting
omorbidities, type of cardiac procedure, previous cardiac surgery,
jection fraction, and New York Heart Association class. In addi-
ion, predictor variables that were significant at a 2-tailed P value
f less than .15 in univariate analyses were entered into the full
odel.
ata Analysis
aseline demographics for patients who received statin treatment
ere compared with those of patients who had not received statin
reatment. 2 Tests were used to determine differences among
reated and nontreated patients for categoric variables. The Wil-
oxon rank sum test and t tests were used to compare the 2 groups
or continuous variables. Complete data were available on out-
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Pome variables and statin use for all patients. Complete covariate
ata were available for 3409 patients.
The unadjusted effects of statin use on 30-day morbidity and
ortality were assessed by using logistic regression analysis. Risk-
djusted comparisons were made by using multivariable logistic
egression models after adjustment for preoperative patient risk
actors. In addition, a second method of adjustment using matching
n propensity scores was used. Conditional logistic regression was
sed to analyze these matched pairs and determine the effect of
tatin pretreatment.
ABLE 1. Statin use in the statin-treated group
Type and dose of statin No. treated (%)
Atorvastatin
10 mg 252 (24.14)
20 mg 114 (10.92)
40 mg 52 (5.00)
Simvastatin
10 mg 210 (20.11)
20 mg 238 (22.81)
60 mg 19 (1.82)
Lovastatin
20 mg 60 (5.75)
40 mg 11 (1.05)
Fluvastatin
20 mg 25 (2.39)
40 mg 5 (0.48)
Pravastatin
10 mg 4 (0.38)
20 mg 41 (3.93)
40 mg 13 (1.25)
ABLE 2. Baseline patient characteristics
ariable
emographic
Age
Body surface area
Male, %
isk factors–comorbidities
Current smoker, %
Hypertensive, %
Diabetes, %
Hypercholesterolemia, %
Renal failure, %
NYHA class IV, %
Previous MI, %
Cerebrovascular disease, %
Peripheral vascular disease, %
Immunosuppressive treatment, %
Preoperative use of intra-aortic balloon pump, %YHA, New York Heart Association; MI, myocardial infarction.
The Journal of Thoracicropensity Score Development
his study followed a retrospective and nonrandomized design.
herefore there was no control over which patients received statin
reatment before surgical intervention versus those who did not.
ssues of selection bias and confounding were addressed through
he use of a propensity score, a statistical strategy introduced by
ubin and Rosenbaum as a means of addressing the bias that exists
n observational studies.21,22 Multiple logistic regression was used
n this study to construct propensity scores for statin use. Patients
rom the statin-treated and statin-untreated groups were then
atched on propensity scores, and logistic regression was used to
etermine the effect of statin treatment on morbidity and mortality.
fter matching on propensity score, there were no significant
ifferences between the 2 groups.
esults
he study population was drawn from patients undergoing
lective cardiac surgery during the period from 1994
hrough 2002. The use of preoperative statins increased
rom less than 20% in the initial year of this study to more
han 60% in the final year of this study (P  .001 for time
rend).
Table 1 delineates the type and dose of statin in the
tatin-treated group. No differences in mortality or morbid-
ty outcomes were observed by type of statin used.
Table 2 presents the overall clinical characteristics for
atients treated and not treated with statins. Age and sex
istributions were similar in both groups. Body surface area
as significantly greater in the statin-treated group. This
roup was also more likely to have had a previous MI (P 
0007) or to be diabetic (P  .002), hypertensive (P 
001), or hypercholesterolemic (P  .001).
Not treated
(n  2785)
Statin treated
(n  1044) P value
.39  12.55 63.18  11.2 .64
.93  0.33 1.96  0.22 .007
66.5 66.85 0.836
58.71 58.27 .805
67.02 75.78 .001
28.32 33.33 .002
37.95 79.79 .001
6.78 6.63 .865
34.53 32.06 .143
37.32 52.81 .000
13.91 15.24 .293
15.42 15.64 .863
2.09 2.12 .968
3.48 2.9 .26463
1and Cardiovascular Surgery ● Volume 131, Number 3 681
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CSPUse of other medications before surgical intervention
lso differed between the 2 groups. The statin-treated group
ad a higher percentage of patients treated with -adrenergic
lockers (P  .001), angiotensin-converting enzyme inhib-
tors (P  .016), oral nitrates (P  .001), and aspirin (P 
001). Those not treated with statins had a higher incidence
f digitalis (P  .001) or diuretic use (P  .001, Table 3).
The percentage of patients experiencing 30-day morbid-
ty was significantly less in the statin-treated group (5.9% vs
.3%, P  .05). Statin-treated patients also experienced
ower mortality in the 30-day period (2.5% vs 5.6%, P 
05; Figure 1).
Risk-adjusted outcomes also demonstrated that statin-
reated patients experienced lower odds of operative mor-
ality and morbidity. This was true for the standard risk-
djusted model (adjusted for age, sex, body surface area,
moking, previous MI, cerebrovascular and peripheral vascular
isease, diabetes, ejection fraction, New York Heart Associa-
ion functional class, hypertension, -adrenergic blocker use,
spirin use, use of intra-aortic balloon pump, and operative
ategory), with an odds ratio of 0.55 (95% confidence
ABLE 3. Use of preoperative medications
ariable
Not treated
(n  2785)
Statin treated
(n  1044) P value
-Adrenergic blockers, % 44.11 61.69 .001
igitalis, % 18.87 11.57 .001
alcium antagonists, % 28.98 32.02 .067
ngiotensin-converting
enzyme inhibitors, %
28.08 32.05 .016
ral nitrates, % 38.07 55.11 .001
se of diuretics, % 35.01 29.45 .001
se of aspirin, % 55.28 73.93 .001
igure 1. Unadjusted percentages of 30-day morbidity and mor-
ality for patients pretreated with statins (n  1044) or not treatedcn  2785). *P < .05 versus not treated.
82 The Journal of Thoracic and Cardiovascular Surgery ● Marcnterval [CI], 0.32-0.93) for mortality and 0.76 (95% CI,
.62-0.94) for morbidity. Similar results were seen after
atching patients on treatment propensity scores, with an
dds ratio of 0.51 (95% CI, 0.27-0.94) for mortality and
.71 (95% CI, 0.5500.92) for morbidity (Figure 2). Primary
ause of death for both statin treated and not treated groups
re shown in Figure 3.
CABG or CABG with valve procedures accounted for
pproximately 80% of the sample (n 3113), whereas 20%
nderwent valve repair or replacement only (n  716).
nivariate analysis demonstrated that 30-day mortality was
igher in the valve-only group (7.5% vs 2.0%, P  .001).
tatin use was less common in the valve-only group (7% vs
2%, P  .002). This necessitated controlling for operative
ategory in the risk-adjusted analysis. In addition, the per-
entage of valve-only patients experiencing mortality was
ower for statin-treated patients (1.96% vs 7.5%). This was
ot statistically significant, likely a result of the reduction in
ower caused by the reduced sample size.
iscussion
espite advances in surgical techniques,23,24 hemodynamic
onitoring, and postoperative care, cardiac surgical proce-
ures still incur significant morbidity and mortality.25 Fur-
hermore, a complicated postoperative course will result in
 significant medical cost burden.25 Accordingly, the devel-
pment of strategies to further reduce morbidity and mortality
ssociated with cardiac surgical procedures would be of sig-
ificant clinical import. The 3-hydroxy-3-methylglutaryl coen-
yme A reductase inhibitors (statins) have demonstrated effi-
acy in the reduction of cardiovascular events in primary
nd secondary prevention in varied patient populations,
ncluding surgical populations.3,5,6,15,16,26-31 The overall
Effect of statin treatment
Unadjusted mortality
Unadjusted morbidity
Adjusted mortality
Adjusted morbidity
Propensity matched mortality
ropensity matched morbidity
Odds ratio
igure 2. Comparison on odds ratios for unadjusted, adjusted, and
ropensity-matched models. The solid points represent the odds
atio, and the lines represent the 95% confidence interval. All of
he odds ratios fall below the null value of 1, indicating a
ignificantly reduced risk of 30-day mortality and morbidity out-
ome for patients pretreated with statins (P < .05 vs not treated).
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Poal of the present study was to evaluate whether statin
retreatment exerted an independent effect on 30-day mor-
idity and mortality in a cohort of patients undergoing
ardiac procedures requiring cardiopulmonary bypass. The
nique and important findings of this study were that pre-
perative statin use was independently associated with an
pproximately 40% reduction in 30-day mortality, and an
ffect of similar but lesser magnitude was observed with a
omposite morbidity measure encompassing postoperative
I, stroke, reoperation, renal failure, and infection. Conse-
uently, this study provides a rationale and foundation for
eveloping a pretreatment regimen for statin therapy in
atients before cardiac surgery.
It is becoming increasingly clear that statins have pleio-
ropic effects independent of lipid lowering that could result
n a reduction of adverse postoperative events. These effects
nclude the ability to improve endothelial function, decrease
asoconstriction, suppress the inflammatory response, and
educe thrombosis.13,14,32 In the present study there was a
igh incidence of patients undergoing cardiac surgical pro-
edures who had preexisting comorbid conditions, such as
iabetes, hypertension, and hypercholesterolemia. Thus
hese patients have preexisting endothelial dysfunction,
Figure 3. Comparison of primary cause of mortality in p
not treated (number of events  155). Primary cause of
significant system that began to fail or was the precipita
systems were defined as follows: cardiac, myocard
heart failure; neurologic, stroke, cerebral bleed, emb
insufficiency or failure, pneumonia, adult respiratory
edema; infection, any systemic or organ infection (ie
or cellulitis); renal, renal failure, dialysis, or both; va
embolic event or circulatory dysfunction; other, cause
organ failure, or other surgical intervention that led toave increased levels of circulating inflammatory markers, a
The Journal of Thoracicnd are more prone to vasoconstriction and thrombosis,
hich in turn results in these patients being at greater
perative risk. Notably, the incidence of these comorbid
onditions was significantly higher in the statin-pretreated
roup. However, despite the increased risk conferred by
hese concomitant disease states, the statin-pretreated group
till experienced reduced acute morbidity and mortality. It
as been established that statins exert cardioprotective ef-
ects in high-risk groups. For example, statins have demon-
trated efficacy in reducing rates of cardiovascular events in
iabetic patients, irrespective of their initial cholesterol lev-
ls.28 In addition, statins have been shown to exert even
ore powerful and positive effects on the endothelium in
iabetic patients than in healthy control subjects.9 The
resent study was retrospective and therefore could not
efine the mechanisms behind the observed effects of statins
n postsurgical morbidity and mortality. Nevertheless, the
esults of this study provide the fundamental basis for future
tudies designed to elucidate the possible mechanisms be-
ind these effects.
Numerous large clinical trials have conclusively demon-
trated that statin treatment reduces the risk of cardiovascular
vents for both primary and secondary prevention.3-6,33 Both
ts pretreated with statins (number of events  26) and
ality was defined as the body system that was the first
system that ultimately led to the patient’s death. These
nfarction, arrhythmic disorder, cardiomyopathy, or
, or other neurologic event; pulmonary, respiratory
ess syndrome, ventilator dependence, or pulmonary
is, sternal or wound, subacute bacterial endocarditis,
ar, peripheral (arterial circulation) disorder, such as
than those listed above, accidental, trauma, multiple
ent’s death.atien
mort
ting
ial i
olism
distr
, seps
scul
other
patinimal models and observational studies have shown that
and Cardiovascular Surgery ● Volume 131, Number 3 683
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CSPreoperative statin therapy can have beneficial effects in the
erioperative period.29,31,34,35 In a porcine model pretreat-
ent with atorvastatin for 3 weeks before CABG resulted in
yocardial protection, as evidenced by decreased infarct
ize, improved regional wall motion, and preserved endo-
helial function in the statin-treated animals. These changes
ccurred irrespective of changes in cholesterol levels.35 In
ccordance with our findings, the most recent of the obser-
ational studies reported that preoperative statin treatment
as associated with a significant reduction in 30-day mor-
ality by using multivariate logistic regression analysis.34
lthough this study did not replicate this result in its
ropensity score–matched analysis (likely because of a
oss of statistical power as a result of the matching
trategy), propensity-matched analysis did demonstrate a
ignificant reduction in a composite variable comprised of
0-day mortality and stroke. In the present study our retro-
pective analysis comprises the largest single-institution
tudy to date evaluating the effect of preoperative statin
reatment on morbidity and mortality in patients undergoing
ardiac surgery. Even after adjustment for numerous covari-
tes, patients treated with statins before surgical interven-
ion had greatly lower morbidity and mortality rates. Be-
ause of the much larger sample size in the present study,
he results of both the multivariate logistic regression and
ropensity score–matched analysis show the same reduction
n risk of 30-day mortality. Additionally, our data also show
n approximately 25% reduction in a composite morbidity
easure. In addition, unlike other studies, our patient pop-
lation was not restricted to patients undergoing CABG but
lso included patients undergoing valve repair and replace-
ent procedures. Although including these patients neces-
itated controlling for operative category in our analysis,
his increases the generalizability of our findings and might
lso indicate that the effects of statin pretreatment might
ranscend the cardiac disease process and instead influence
ore intrinsic biologic processes. Because risk models for
alvular heart disease are not as well developed as those for
oronary disease, the risk adjustment strategies used might
ot adequately differentiate results between CABG, CABG-
alve, and valve-only patients. In addition, our ability to
nvestigate the effects of statin pretreatment in the valve-
nly group is limited by both reduced sample size and a
imited number of events in the statin-treated valve-only
roup. However, analysis of the valve-only subsample was
uggestive that valve-only patients also experienced a ben-
ficial effect of statin pretreatment, and this result could
orm the basis of future studies.
The present study also detected differences in medication
rofiles between the 2 groups. Notably, the statin-pretreated
roup also took more -adrenergic receptor antagonists,
ngiotensin-converting enzyme inhibitors, and aspirin.
he increased use of these medications is likely due to v
84 The Journal of Thoracic and Cardiovascular Surgery ● Marche greater observed rate of previous MI observed in the
tatin-pretreated group. In large observational studies
oth  -adrenergic blockers36 and aspirin37 have demon-
trated a survival benefit in patients undergoing CABG.
ccordingly, we adjusted for the use of these medica-
ions in our analysis. Statin pretreatment still exhibited an
ndependent association with reduced postsurgical mor-
idity and mortality. However, it is possible that the
igher rates of cardioprotective medications seen in the
tatin-treated group might indicate these patients were
etter prepared for surgical intervention and received
ore preoperative care than the non–statin-treated group.
t has been demonstrated that a patient cohort with in-
reased use of the combination of statins, aspirin, and
-adrenergic receptor blockers after a coronary event had
ewer recurrent MIs and lower rates of cardiac mortality.38
uture studies that model the potential additive effects, syn-
rgistic effects, or both of statins with other medications
ould be warranted.
Although the present study clearly demonstrated the pos-
tive effect of statin treatment, the necessary dosing regimen
o establish these effects has yet to be established. A small
bservational study demonstrated that short-term statin ther-
py (3-5 days) preoperatively has been associated with
educed cardiovascular adverse events after CABG.29 In
ddition, statins have shown rapid effects on both endothe-
ial function and inflammatory markers, producing changes
n as little as 24 hours to 1 week.10 Further studies are
ecessary to define the optimal temporal window for statin
retreatment before cardiac procedures. Another consider-
tion in the present study is that although 2 statistical
ethods were used to control for potential confounding
ariables, there might be unmeasured covariates that are
nfluencing the association seen between statin pretreatment
nd morbidity and mortality outcomes. Only prospective
andomization can ensure (on average) that there are no
ystematic differences in covariates. We could not use that
trategy because of the retrospective nature of this study.
owever, the propensity score methodology used allows a
uasirandomization, which should result in unbiased esti-
ates of the treatment effect.22
Two questions that remain unanswered by this study are
hether the statin-treated group met target levels of LDL
ontrol and whether there were significant differences in
DL levels between the groups. If no significant differences
xisted, this would contribute further evidence that the
emonstrated beneficial effects of statins in this study were
ue to pleiotropic effects. Unfortunately, preoperative levels
f LDL were not recorded in each group, and thus whether
significant difference in LDL levels existed between the
roups cannot be determined.
These limitations notwithstanding, the present study pro-ides direct evidence that statin pretreatment before cardiac
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Purgical procedures imparts a beneficial effect with regard
o reduced rates of acute morbidity and mortality. Our data
rovide a foundation for prospective studies evaluating the
ptimal statin regimen to initiate before cardiac procedures.
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